PRISIM
Research type
Research Study
Full title
Psoriatic, Rheumatoid, Inflammatory arthritis; Study of Immune Mechanisms (PRISIM Study)
IRAS ID
66106
Contact name
Bruce Kirkham
Contact email
Sponsor organisation
Director of Research Management, Director of Administration (Health Schools), King's College London
Eudract number
N/A
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Psoriatic Arthritis (PsA) is a painful inflammatory joint disease affecting 0.1-1% of the population and 10-30% of people with the skin condition psoriasis. PsA is a seronegative spondyloarthropathy (SpA), a class of inflammatory arthritis including ankylosing spondylitis, reactive and inflammatory bowel disease related arthritis. Joint damage, a serious outcome of PsA, occurring in 40% of patients, is not possible to predict. Immune cells, including T-cells, and their pro-inflammatory products (cytokines),eg interleukin-17, may play a role in joint damage.
The aims of this study are:
(1) characterise the contribution of IL-17 producing immune cells to the pathogenesis of PsA.
(2) Investigate if levels of specific immune cells or joint ultrasound can be used to predict which patients will develop joint damage. And,
(3) identify common inflammatory pathways in skin and joints in participants with psoriasis and PsA and compare these with other forms of arthritis including rheumatoid arthritis, spondyloarthropathies and osteoarthritis.We will recruit adults with arthritis and psoriasis attending rheumatology outpatient clinics at Guys and St Thomas', Kings College and Royal Berkshire NHS Foundation Trusts, and Frimley Park Hospital. We will collect blood, joint (synovial) fluid and, sometimes, small samples of joint tissue(synovial tissue) and skin. As controls we will collect blood from healthy volunteers. Patients may donate samples more than once. Joint ultrasound will assess disease severity and guide synovial tissue biopsies. X-rays to identify erosions will be performed if not available from routine care. In the laboratory, we will investigate immune cells, comparing levels and functions of different cells, regulation, proliferation, gene expression and cytokine production.
This study will improve our understanding of the mechanisms of joint inflammation and erosion. Predicting patients at risk of joint erosions will inform treatment decisions thereby improving patient care. The results may also provide a novel insight into potential therapeutic targets.
REC name
London - Harrow Research Ethics Committee
REC reference
17/LO/1940
Date of REC Opinion
28 Nov 2017
REC opinion
Favourable Opinion